Neuland Laboratories Limited. — Earnings Release 2021

Feb 3, 2021

Neuland Laboratories Limited Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/11 3 Road No. 2, Banjara Hills Hyderabad - 500 034. Telangana, India.

Tel: 040 67611600 / 67611700 Email: neuland@neulandlabs.com www.neulandlabs.com

February 3, 2021

To BSE Limited Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai - 400 001

To The National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex, Sandra (E) Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sirs,

Sub: Compliance with Regulation 47(1)(b) of the SEBI Listing Regulations, 2015

Please find attached herewith copies of the newspaper publication of Un-audited Financial Results for the quarter ended December 31, 2020, published in Financial Express and Andhra Prabha on February 3, 2021 for your reference.

This is for your information and records.

Thanking you,

Yours faithfully,

For Neuland L Limited

Sarada Bha a *

Company Secretary

Encl : As above

ಬುಧವಾರಂ 3 ಫಿಬ್ರವೆಲಿ 2021			ವಾದರಾಬಾದಿ
NEULAND LABORATORIES LIMITED
	(CIN: L85195TG1984PLC004393)
Regd. office: Sanali Info park, 'A' Block, Ground floor				NEULAND
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034
EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2020			(Amount in lakhs of ₹, unless otherwise stated)
SI.ParticularsNo.	31.12.2020	31.12.2019	Quarter Ended Quarter Ended Nine months Ended Nine months Ended31.12.2020	31.12.2019
1Revenue from operations	24,539.18	20,384.37	69,220.84	57,106.89
2Net profit for the period before tax	3,194.77	1,567.18	8,094.34	3,572.45
3Net profit for the period after tax	2,673.52	1,111.04	6,333.81	2,550.62
Total comprehensive income for the period4	2,686.09	1,085.27	6,325.67	2,472.15
Paid-up Equity Share Capital (Face value - ₹ 10 each)5Earnings Per Share (of ₹ 10 each) (In absolute ₹ terms)	1,290.05	1,290.05	1,290.05	1,290.05
(a) Basic		20.848.66	49.37	19.88
(b) Diluted		20.848.66	49.37	19.88
Note 1: The financial results for the quarter and nine months ended 31 December 2020 have been reviewed by the AuditCommittee and approved by the Board of Directors at their meeting held on 2 February 2021.
Note 2: Key Standalone Financial Information:				(Amount in lakhs of $\bar{z}$ )
Particulars	31.12.2020	31.12.2019	Quarter Ended Quarter Ended Nine Months Ended Nine Months Ended31.12.2020	31.12.2019
Revenue from operations	24,539.18	20,361.97	69,220.84	57,084.49
Net profit for the period before tax	3,185.82	1,557.46	8,064.62	3,541.90
Net profit for the period after tax	2,667.17	1,104.26	6,306.69	2,523.01
Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges underRegulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of theUnaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.comand on the Company's website www.neulandlabs.com				By Order of the Board
Place: Hyderabad
Date: 2 February 2021
WEDNESDAY, FEBRUARY 3, 2021NEULAND LABORATORIES LIMITEDRegd. office: Sanali Info park, 'A' Block, Ground floor8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034	(CIN: L85195TG1984PLC004393)		FINANCIAL EXPRESS	neuland
EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2020			(Amount in lakhs of ₹, unless otherwise stated)
SI.ParticularsNo.	31.12.2020	31.12.2019	Quarter Ended Quarter Ended Nine months Ended Nine months Ended31.12.2020	31.12.2019
	24,539.18	20,384.37	69,220.84	57,106.89
Revenue from operations	3,194.77	1,567.18	8,094.34
Net profit for the period before taxNet profit for the period after tax	2,673.52	1,111.04	6,333.81	3,572.452,550.62
Total comprehensive income for the period	2,686.09	1,085.27	6,325.67	2,472.15
1234Paid-up Equity Share Capital (Face value - ₹ 10 each)5Earnings Per Share (of ₹ 10 each) (In absolute ₹ terms)	1,290.05	1,290.05	1,290.05	1,290.05
(a) Basic		20.848.66	49.37	For Neuland Laboratories LimitedDr. D.R.RaoExecutive Chairman(DIN 00107737)19.88

Note 2: Key Standalone Financial Information:

Note 2: Key Standalone Financial Information:(Amount in lakhs of $\zeta$ )
Particulars	31.12.2020	31.12.2019	31.12.2020	Quarter Ended Quarter Ended Nine Months Ended Nine Months Ended31.12.2019
Revenue from operations	24,539,18	20, 361, 97	69,220.84	57.084.49
Net profit for the period before tax	3.185.82	1.557.46	8.064.62	3.541.90
Net profit for the period after tax	2.667.17	1,104.26	6,306.69	2,523.01

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

By Order of the Board For Neuland Laboratories Limited Dr. D.R.Rao

Executive Chairman

(DIN 00107737)